Assertio Holdings (ASRT) Stock

About Assertio Holdings

Assertio Holdings, Inc. is a specialized pharmaceutical company focused on developing and commercializing therapeutic solutions across key medical domains, including neurology, hospital care, and pain and inflammation management. Among its portfolio, Assertio offers INDOCIN, available as both an oral solution and a suppository. This medication addresses conditions such as moderate to severe rheumatoid arthritis (including acute flare-ups), ankylosing spondylitis, osteoarthritis, acute painful shoulder, and gouty arthritis. The company's offerings also encompass CAMBIA, an NSAID specifically formulated to alleviate symptoms associated with migraine headaches, including nausea, light sensitivity (photophobia), and sound sensitivity (phonophobia). Zipsor, another NSAID, is indicated for managing mild to moderate acute pain. For more significant short-term pain relief, SPRIX, also an NSAID, provides analgesia comparable to opioid-level treatments for moderate to moderately severe pain. Rounding out its product line is Otrexup, a prescription methotrexate delivered via a convenient single-dose auto-injector. This therapy targets severe, active rheumatoid arthritis in adults and active polyarticular juvenile idiopathic arthritis in pediatric patients. Initially incorporated as Assertio Therapeutics, Inc. in 1995, the organization rebranded to Assertio Holdings, Inc. in May 2020 and maintains its corporate headquarters in Lake Forest, Illinois.

Assertio Holdings is led by CEO Mark L. Reisenauer, employs 58 people, headquartered in US, publicly traded since 1997.

Assertio Holdings (ASRT) stock trades at $23.44 with a market capitalization of $151.47M. The stock is valued at a negative price-to-earnings (P/E) ratio of -4.95, reflecting a net loss over the last twelve months, price-to-book of 1.61, price-to-sales of 1.48. Over the past 52 weeks the stock has ranged between $8.61 and $23.50, and currently trades at or near its 52-week high.

On profitability, Assertio Holdings generates a return on equity (ROE) of -31.91% (negative, reflecting a net loss), return on capital employed of -18.09%, an operating margin of -14.29%, a net profit margin of -34.94%.

Official website: www.assertiotx.com

Assertio Holdings by the numbers, 2016–2025

Between 2016 and 2025 Assertio Holdings reported revenue of $456.0M rising to $119.0M, a change of -73.9% across 10 years. Compounded, revenue has grown 2.0% a year over five years, -8.6% over three, -4.8% over the last twelve months. Net profit rose to $-30.0M.

Operating margin went from 5.4% in 2016 to -14.5% in 2025, a fall of 19.9 percentage points. The most recent net margin is -34.94%. On a trailing twelve-month basis to Mar '26, revenue is $102.0M and net profit $-36.0M.

Borrowings fell from $719.0M to $39.0M, cash from operations was $-28.0M in the latest year, positive in 8 of the last 10.

Return on equity has averaged -48.6% over five years, and was -31.9% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Assertio Holdings (ASRT) — frequently asked questions